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Abstract
Background: TGFBR1*6A is a common hypomorphic variant of transforming growth factor β receptor 1 (TGFBR1). 
TGFBR1*6A is associated with an increased cancer risk, but the association of this polymorphism with osteosarcoma 
remains unknown. We have measured the frequency of TGFBR1*6A variants in osteosarcoma cases and controls.
Methods: Our case-control study is based on 168 osteosarcoma patients and 168 age- and gender-matched controls. 
Blood samples were obtained and the TGFBR1*6A variant determined by PCR amplification and DNA sequencing. The 
odds ratio (OR) and 95% confidence interval (95% CI) for the TGFBR1*6A polymorphism were calculated by 
unconditional logistic regression, adjusted for both age and gender. Three models - dominant, additive and recessive - 
were used to analyze the contribution of the TGFBR1*6A variant to osteosarcoma susceptibility.
Results: Heterozygotic and homozygotic TGFBR1*6A variants represented 50.4% and 6.0% of the 168 cases, whereas 
the controls had 18. 5% and 1.3%, respectively. ORs for homozygosity and heterozygosity of the TGFBR1*6A allele were 
4.6 [95% CI, 2.33-7.97] and 2.9 [95% CI, 1.59-5.34] in the additive model. There were significant increases in the 
TGFBR1*6A variants in osteosarcoma cases compared to control in all 3 models. Further analysis showed that 
TGFBR1*6A genotypes were not associated with gender, age, or tumor location. However, TGFBR1*6A was significantly 
associated with less metastasis.
Conclusions: TGFBR1*6A, a dominant polymorphism of TGFBR1, is associated with increased susceptibility and 
metastasis spread of osteosarcoma.
Background
Osteosarcoma is the primary malignancy of bone that has
peak occurrences in adolescence and after 50 years of age
[1,2]. Although there have been many studies on its
genetics, biology, pathology and clinical aspects, the eti-
ology of osteosarcoma is not well understood. Screening
large series of children with osteosarcoma showed that
~4% carried a constitutional germline mutation in p53,
suggesting a genetic predisposition of osteosarcoma [3].
TGF-β signaling plays an important role in the develop-
ment of tumors because it is a potent inhibitor of cell pro-
liferation in most cell types [4,5]. Tumors frequently lose
responsiveness to TGF-β-mediated growth inhibition due
to disruption in the TGF-β signaling pathway [6]. TGF-β
regulates gene expression and enzymes activity in osteo-
sarcoma, and modulates the effects of hormones on oste-
osarcoma, suggesting that TGF-β signaling is involved in
the development of osteosarcoma [7-9]. TGF-β binds to
its receptor, TGF-β receptor 2 (TGFBR2), which forms a
heteomeric complex with TGF-β receptor 1 (TGFBR1).
This leads to the transduction of the TGF-β signal from
the cell surface to the cytoplasm [10,11]. Mutation of
TGFBR1 may result in a high risk of certain cancers. For
example, TGFBR1*6A is a common mutation of TGFBR1,
and this variant is generated by deletion of 3 GCG triplets
that coding for alanines within a 9 alanine (*9A) sequence
at exon 1. TGFBR1*6A mutation can lead to the develop-
ment of breast cancer, ovarian cancer, and renal cell carci-
noma amongst others [12-15]. However, the relationship
between TGFBR1*6A mutation and osteosarcoma occur-
rence remains unknown. There have been no reports
about the prevalence of TGFBR1*6A mutation in osteo-
sarcoma. Clarification of the relationship between
TGFBR1*6A and osteosarcoma may indicate a role of
TGF-β signaling in the etiology of osteosarcoma and pro-
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vide clues that might help to guide treatment of this dis-
eases. To clarify this relationship, we have analyzed
TGFBR1 variation in clinical cases of osteosarcoma and
normal controls. TGFBR1*6A positively correlated with
the occurrence of osteosarcoma.
Methods
Study Subjects
Patients with osteosarcoma admitted to the Department
of Orthopedics at Tangdu Hospital from January 2001 to
March 2009 were selected to participate in the study,
making a total of 168 patients. The mean age in the cases
was 30 years (range 10-71 years). All the cases were diag-
nosed without a familial cancer syndrome. As controls,
DNA from 168 blood donors of mixed gender collected at
Tangdu Hospital, Xi'an, China, were used. The controls
were disease-free. Informed consent was obtained from
all the subjects, and the study was approved by the ethical
committee at Tangdu Hospital.
TGFBR1*6A genotyping
TGFBR1*6A genotyping invovled the protocol of Song et
al [14]. PCR amplification of exon 1 of TGFBR1 was per-
formed with the following primers: Forward 5'-GAG
GCG AGG TTT GCT GGG GTG AGG-3' and Reverse
5'-CAT GTT TGA GAA AGA GCA GGA GCG-3'. The
reactions were based in the protocol given by Invitrogen
(Paisley, UK) in a total volume of 25 μl containing 50 ng
DNA and 1.25 U Platinums Taq DNA polymerase. Fluo-
rescently labeled PCR products were separated with an
ABI 377 DNA Sequencer. Genotypes analysis was done
with the GENESCANTM and GENOTYPERTM soft-
ware. A product size of 247 bp represented the wild-type
TGFBR1 (9A) allele, whereas a product size of 255 bp
represented the TGFBR1*6A allele.
Statistical analysis
Genotype distribution in osteosarcoma cases and con-
trols was tested for the Hardy-Weinberg equilibrium, and
the 2 variants were shown to be in equilibrium in both
the patients and the controls. Differences in TGFBR1*6A
variant carrier frequencies between cases and controls
for the dominant and recessive models were assessed by
the χ2 test. The Armigate treand test was used to calculate
P for trends in the additive model. Results are presented
as odds ratios (ORs) with 95% test-based confidence
intervals (CIs). All P values were 2-sided and P < 0.05 was
considered significant.
Results
TGFBR1*6A genotypes and osteosarcoma susceptibility
The frequencies of 9A/6A and 6A/6A genotypes were sig-
nificantly different between the cases and controls. In 168
cases, 9A/9A, 9A/6A and 6A/6A genotypes re[resented
107, 51 and 10, respectively. In 168 controls, the geno-
types of 9A/9A, 9A/6A and 6A/6A were 134, 31 and 3,
respectively. Heteozygotic and homozygotic TGFBR1*6A
variants were 50.4% and 6.0% in total 168 cases, while
they were 18.45% and 1.29% respectively in total 168 con-
trols. When the data were analyzed with the dominant,
additive and recessive models, there were significant
increases in TGFBR1*6A variants in osteosarcoma cases
compared to control in all of the (P < 0.01). The result are
shown in Table 1.
TGFBR1*6A genotypes and clinical parameters of 
osteosarcoma
No significant statistic differences were shown in the
association of TGFBR1*6A genotypes with clinical
parameters between males and females. Nor was any sig-
nificant difference found between patirnts under 20 and
those over 20. The location of osteosarcomas in long
Table 1: TGFBR1*6A genotypes in controls and patients with osteosarcoma
TGFBR1*6A 
genotypes
Cases (n = 168)
number (%)
Controls (n = 168)
number (%)
OR
[95% CI]
P value
Dominant model
9A/9A 107 (63.69) 134 (79.76) 1 (ref)
9A/6A and 6A/6A 61 (36.31) 34 (20.24) 3.48 [1.92-6.17] 0.0011*
Additive model
9A/9A 107 (63.69) 134 (79.76) 1 (ref)
9A/6A 51 (30.36) 31 (18.45) 2.91 [1.59-5.34]
6A/6A 10 (5.95) 3 (1.79) 4.59 [2.33-7.97] 0.0018**
Recessive model
9A/9A and 9A/6A 158 (94.05) 165 (98.21) 1 (ref)
6A/6A 10 (5.95) 3 (1.79) 4.03 [1.99-6.87] 0.0001*
* χ2-test; ** p for trend (Armitage's treand test)Hu et al. BMC Cancer 2010, 10:169
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tubular bones and the axial skeleton was not significantly
associated with a particular mutation of the TGFBR1*6A
genotype. However, in cases with distant metastasis, the
frequency of TGFBR1*6A genotypes was significantly
decreased compared with those without distant metasta-
sis (P < 0.01). The result are shown in Table 2.
Discussion
The 9A/6A and 6A/6A genotypes of TGFBR1 have a sig-
nificantly higher frequency in osteosarcoma cases than in
controls. TGFBR1*6A is a dominant susceptibility allele
in the occurrence of osteosarcoma. The retrospective,
non-randomized nature of most case-control studies lim-
its the conclusion that can be reached from them.
Because the subjects our study were from different
regions of China for a long period from 2001 to 2009, the
results have been more informative.
The association between TGFBR1*6A and tumorigene-
sis seems to be different in our case. Previous reports
indicated that TGFBR1*6A increased susceptibility of
tumorigenesis and development in renal cell carcinoma,
ovarian cancer, and breast cancer [12-14,16], although
others found no association of TGFBR1*6A with the
occurrence of lung cancer, prostate cancer, colon cancer
and bladder cancer [17-21]. Thus TGFBR1*6A genotypes
mya be specifically related to only certain kinds of cancer,
in a population- and tissue-related manner.
TGF-β signaling may not be the same in different tis-
sues, which might explain the tissue-related manner of
the association between TGFBR1*6A genotypes and can-
cer development. TGF-β signaling seems to be involved
in tumorigenesis because it may behave aberrantly in its
role as a potent inhibitor of cell proliferation in most epi-
thelial and lymphoid cells [22]. Tumors frequently lose
responsiveness to TGF-β-mediated growth inhibition due
to disruption of its signaling pathway [23]. Loss of expres-
sion of TGF-β receptors may be as a prognostic factor in
patients with renal cell carcinoma [24]. Receptor interac-
tions at the level of the plasma membrane have been
implicated in the regulation of TGF-β signaling pathway.
In a mice model, constitutively reduced TGFBR1-medi-
ated TGF-β signaling significantly enhances colorectal
cancer development and more rapid tumor cell prolifera-
tion [25]. Tissue-specific expression of TGF-β receptors
could explain the varying effects of TGF-β in different tis-
sues. For example, targeted deletion of TGF-β receptors
in mouse mammary epithelium results in excessive lobu-
lar-alveolar cell proliferation [26], but in contrast, no
developmental changes were apparent upon deletion of
TGF-β receptors in the epithelia of the oral cavity, esoph-
agus, forestomach, pancreas and intestine of mice [27-
29]. The unresponsiveness of some tissues to TGF-β sig-
naling may explain their insensitivity to TGFBR1*6A vari-
ant, and vice versa.
Our study firstly demonstrates the significant associa-
tion between TGFBR1*6A and osteosarcoma, which may
be due to the important role of TGF-β signaling in the
control of osteosarcoma. Some data indicates that TGF-β
can be an important factor in the occurrence of osteosar-
coma. TGF-β receptor is expressed in osteosarcoma [30].
TGF-β increases alkaline phosphatase (AP) activity in the
rat osteoblastic cell line, ROS 17/2.8, and may promote
Table 2: Associations of TGFBR1*6A genotypes with clinical parameters
Characteristics Total Cases (n = 168) TGFBR1*6A genotypes p value
9A/9A (%) 9A/6A + 6A/6A (%)
Gender
Male * 103 66 (64.08) 37 (35.92)
Female 65 41 (63.08) 24 (36.92) 0.99
Age
> 20 * 49 32 (65.31) 17 (34.69)
≤ 20 119 75 (63.03) 44 (36.97) 0.86
Location
long tubular 
bones *
137 86 (62.77) 51 (37.23)
axial skeleton 31 21 (67.74) 10 (32.26) 0.13
Distant metastasis
Without * 140 85 (60.71) 55 (39.29)
With 28 22 (78.57) 6 (21.43) 0.001
* were used as the reference.Hu et al. BMC Cancer 2010, 10:169
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osteoblastic differentiation in rat osteosarcoma cells [31].
We found that TGFBR1*6A genotypes are significant
associated with osteosarcoma, which lends support to the
fact that TGF-β signaling plays a vital role in the occur-
rence of osteosarcoma. The TGFBR1*6A allele encodes a
type I receptor of TGF-β with reduced growth-inhibitory
signaling activity [32]. The genetic variant of TGFBR1*6A
could represent a functional modification in the TGF-β
signaling pathway in osteosarcoma. Although this may
not be necessary in determining the occurrence of osteo-
sarcoma, TGFBR1*6A variants appear to increase suscep-
tibility to osteosarcoma.
Osteosarcoma has a high incidence in young children
and is often located in long tubular bones [33]. Therefore,
we analyzed the association of TGFBR1*6A with some
clinical parameters including gender, age, location and
distant metastasis. Groups are usually divided at the age
of 20, We found no significant association between the
two groups above and below this age, and therefore
TGFBR1*6A variants are not associated with age. In addi-
tion, TGFBR1*6A variants is not associated with the loca-
tion of osteosarcoma, i.e. when frequency in long tubular
bones and axial skeleton were compared. Therefore,
TGFBR1*6A variants increased the susceptibility of oste-
osarcoma universally but not specifically to some cases
with different gender, age and location of the tumor. This
indicates that TGFBR1*6A makes for some functional
modification of TGF-β signaling which stimulates the
occurrence of osteosarcoma without regard to gender,
age and location.
Analysis of distant metastasis, however, showed that
TGFBR1*6A is significantly related with metastasis in
osteosarcoma. The decreased risk of distant metastasis of
osteosarcoma in TGFBR1*6A variants suggests that TGF-
β signaling is involved in the metastasis of osteosarcoma.
Tumor metastasis is a complex process and many factors
are involved in this process, TGF-β is only one of these
factors. For example, TGF-β promotes tumor metastasis
in cancer [34-36]. Although the functional variants of
TGFBR1*6A increases susceptibility to osteosarcoma, it
decreases the probability of metastasis. TGFBR1*6A has
been shown to enhance the migration and invasion of
MCF-7 breast cancer cells [37]. Our finding of decreased
metastasis in osteosarcoma cases with TGFBR1*6A con-
trasts with the result with in breast cancer cells. Since
tumor cells may exhibit mutations, making their geno-
types different from normal tissues, we examined the
possibility of loss of homozygosity of TGFBR1 in osteo-
sarcoma tissues in 10 cases with distant metastasis.
TGFBR1*6A genotypes were the same as observed with
blood samples (data not shown), with no loss of homozy-
gosity of TGFBR1 in the tumor samples. Although there
are differences between our results and those obtained
with breast cancer cells, site specificity and tumor speci-
ficity for the role of TGFBR1*6A may be the reason for
the difference since TGF-beta signaling differs within tis-
sues of the body.
Conclusions
This case-control study shows a significant statistical
association between TGFBR1*6A variant and osteosar-
coma in a Chinese population. The TGFBR1*6A variant is
also significantly associated with the distant metastasis of
osteosarcoma in the Chinese population studied.
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